National, September 04, 2025 : Patient Service Programs (PSPs) are rapidly becoming a central pillar of healthcare worldwide, shifting the focus from one-time prescriptions to continuous patient engagement and measurable health outcomes. Globally, PSPs have grown into a USD 70 billion industry, yet in India they remain a largely untapped opportunity.
Traditionally, PSPs in India were driven primarily by multinational pharmaceutical companies, with Saarathi Healthcare emerging as the pioneering player in this space. Saarathi built its reputation by designing patient-centric programs for chronic disease management and establishing a multinational client base. With the acquisition of a majority stake in Saarathi — and moving toward full ownership — QMS Medical Allied Services Ltd. (QMS MAS) has unlocked greater participation for Indian pharma companies in PSPs, reshaping the way healthcare is delivered.
“Our vision is to redefine PSPs as tech-enabled ecosystems that not only support patients but also drive measurable health outcomes,” said Mahesh Makhija, Founder, Chairman & Managing Director, QMS MAS.
Scale & Reach
- QMS MAS and Saarathi together have already supported 2.5 lakh patients across 100+ cities, with programs spanning diabetes, cardiology, respiratory care, and other chronic conditions.
- The company services over 130 institutional clients, including 50 leading pharma companies, through a robust network covering 5,000+ pin codes.
- QMS MAS leverages a strong healthcare workforce, including a 900+ dietician network and 135 certified DMLTs, supported by advanced diagnostic devices, each covering an area radius of 35 km.
Beyond PSPs: A Holistic Healthcare Platform
With 31 years of experience, QMS MAS has evolved into a preferred promotions partner for pharmaceutical companies in India, building bridges between pharma, doctors, and patients. From launching its own Q-Devices brand with Kapil Dev as brand ambassador to entering the hospital supply solutions segment (covering stents, surgical instruments, and treatment-based consumables), the company has consistently expanded its portfolio to meet the changing needs of India’s healthcare ecosystem.
The integration with Saarathi has provided unmatched expertise in patient engagement, adding significant depth to QMS MAS’s service vertical. Full ownership will allow QMS MAS to:
- Seamlessly integrate Saarathi’s PSP models into its ecosystem.
- Unlock synergies to scale programs across India.
- Innovate in delivery models through digital health, AI-driven screening, real-time monitoring, and data analytics.
Driving Growth with Purpose
In Q1 FY26, QMS MAS reported 54% revenue growth and 31.65% PAT growth, fuelled by regulatory clarity, strategic expansion, and operational excellence. Importantly, the company’s guiding principle is to balance business growth with social impact by maintaining quality, credibility, and patient-first standards.
Looking Ahead
Chronic care in India demands more than prescriptions — it requires continuous education, counselling, lifestyle support, and therapy adherence. QMS MAS’s PSPs are bridging these gaps, moving the focus from illness management to wellness empowerment.
Over the next five years, PSPs are expected to evolve into integrated, technology-driven ecosystems at the heart of patient engagement. QMS MAS, with Saarathi’s legacy and its own scale, aims to lead this evolution — bringing pharma, healthcare professionals, and patients together on a unified platform to deliver better outcomes and stronger trust.
PSPs will no longer remain exclusive to pharma companies — corporates, insurers, and even co-working spaces are beginning to explore these tools to engage with their stakeholders, reflecting the growing potential of patient-centric programs in India.
